Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Tiziana Life Sciences Ltd. < Previous 1 2 Next > Tiziana Life Sciences Appoints New Chief Executive Officer August 19, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule August 14, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Granted FDA Fast Track Designation July 24, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Receives $3.4 Million in Non-Dilutive Funding June 28, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab June 26, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis June 11, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab June 06, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab June 04, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research May 30, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab May 13, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab April 25, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program April 23, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program April 22, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today® April 19, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology April 18, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology April 11, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease March 05, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients January 08, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024 January 05, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation January 05, 2024 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis December 19, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar December 04, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis November 30, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023 November 01, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment October 18, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab October 16, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS) October 13, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress October 11, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis September 26, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference September 08, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tickers TLSA < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.